Clinical Trials
29 trialsNCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT07543783 2026-04-28
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
NCT05864105 2025-03-12
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Biotheus Inc.
Phase 2 Active not recruiting
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT02973685 2023-06-12
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
Sun Yat-sen University
Phase 3 Completed
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05029973 2023-02-08
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05718492 2023-02-08
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
Sun Yat-sen University
Phase NA Recruiting
NCT05476432 2022-12-09
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University
Phase 3 Recruiting
NCT05617430 2022-11-15
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05231382 2022-05-24
Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT03164382 2020-12-16
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT02774187 2019-12-05
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02534337 2019-06-04
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT02981498 2019-03-06
Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03812783 2019-01-23
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03469479 2018-08-02
Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Sun Yat-sen University
Phase 3 Unknown
NCT03048123 2017-02-09
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
Sun Yat-sen University
Phase 2 Completed
NCT02738697 2016-11-02
Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
Sun Yat-sen University
Phase 3 Unknown
NCT02452853 2015-05-25
HR Combined With FOLFOX4 for HCC With PVTT
Sun Yat-sen University
Phase 2 Unknown